206 related articles for article (PubMed ID: 37363820)
1. A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma.
Uson PLS; Bearss J; Babiker HM; Borad M
Expert Opin Drug Saf; 2023; 22(8):637-641. PubMed ID: 37363820
[TBL] [Abstract][Full Text] [Related]
2. Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.
Shi GM; Huang XY; Wen TF; Song TQ; Kuang M; Mou HB; Bao LQ; Zhao HT; Zhao H; Feng XL; Zhang BX; Peng T; Zhang YB; Li XC; Yu HS; Cao Y; Liu LX; Zhang T; Wang WL; Ran JH; Liu YB; Gong W; Chen MX; Cao L; Luo Y; Wang Y; Zhou H; Yang GH; Fan J; Zhou J
Cancer Med; 2023 Feb; 12(4):4137-4146. PubMed ID: 36127767
[TBL] [Abstract][Full Text] [Related]
3. Pemigatinib: A Review in Advanced Cholangiocarcinoma.
Frampton JE
Target Oncol; 2024 Jan; 19(1):107-114. PubMed ID: 38206555
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other Rearrangement.
Patel TH; Marcus L; Horiba MN; Donoghue M; Chatterjee S; Mishra-Kalyani PS; Schuck RN; Li Y; Zhang X; Fourie Zirkelbach J; Charlab R; Liu J; Yang Y; Lemery SJ; Pazdur R; Theoret MR; Fashoyin-Aje LA
Clin Cancer Res; 2023 Mar; 29(5):838-842. PubMed ID: 36206041
[TBL] [Abstract][Full Text] [Related]
5. Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies.
Parisi A; Delaunay B; Pinterpe G; Hollebecque A; Blanc JF; Bouattour M; Assenat E; Ben Abdelghani M; Sarabi M; Niger M; Vivaldi C; Mandalà M; Palloni A; Bensi M; Garattini SK; Tougeron D; Combe P; Salati M; Rimini M; Cella CA; Tucci M; Diana A; Mori E; Longarini R; Artru P; Roth G; Evesque L; Vienne A; Turpin A; Hiret S; Bourgeois V; Herve C; Paulon R; Stacoffe M; Malka D; Neuzillet C; Edeline J; Lievre A; Guimbaud R; Chapda MCP; Rimassa L; Giampieri R; Valle J; Berardi R; Fares N
Eur J Cancer; 2024 Mar; 200():113587. PubMed ID: 38340384
[TBL] [Abstract][Full Text] [Related]
6. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Abou-Alfa GK; Sahai V; Hollebecque A; Vaccaro G; Melisi D; Al-Rajabi R; Paulson AS; Borad MJ; Gallinson D; Murphy AG; Oh DY; Dotan E; Catenacci DV; Van Cutsem E; Ji T; Lihou CF; Zhen H; Féliz L; Vogel A
Lancet Oncol; 2020 May; 21(5):671-684. PubMed ID: 32203698
[TBL] [Abstract][Full Text] [Related]
7. Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic Profiling.
Silverman IM; Li M; Murugesan K; Krook MA; Javle MM; Kelley RK; Borad MJ; Roychowdhury S; Meng W; Yilmazel B; Milbury C; Shewale S; Feliz L; Burn TC; Albacker LA
J Mol Diagn; 2022 Apr; 24(4):351-364. PubMed ID: 35176488
[TBL] [Abstract][Full Text] [Related]
8. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V; Iannotti NO; Gutierrez M; Smith DC; Féliz L; Lihou CF; Tian C; Silverman IM; Ji T; Saleh M
Ann Oncol; 2022 May; 33(5):522-533. PubMed ID: 35176457
[TBL] [Abstract][Full Text] [Related]
9. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Uson Junior PLS; Borad MJ
Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
[TBL] [Abstract][Full Text] [Related]
10. FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with
Bekaii-Saab TS; Valle JW; Van Cutsem E; Rimassa L; Furuse J; Ioka T; Melisi D; Macarulla T; Bridgewater J; Wasan H; Borad MJ; Abou-Alfa GK; Jiang P; Lihou CF; Zhen H; Asatiani E; Féliz L; Vogel A
Future Oncol; 2020 Oct; 16(30):2385-2399. PubMed ID: 32677452
[TBL] [Abstract][Full Text] [Related]
11. Clinicogenomic Analysis of
Silverman IM; Hollebecque A; Friboulet L; Owens S; Newton RC; Zhen H; Féliz L; Zecchetto C; Melisi D; Burn TC
Cancer Discov; 2021 Feb; 11(2):326-339. PubMed ID: 33218975
[TBL] [Abstract][Full Text] [Related]
12. Robust Response to Futibatinib in a Patient With Metastatic FGFR-Addicted Cholangiocarcinoma Previously Treated Using Pemigatinib.
Rengan AK; Denlinger CS
J Natl Compr Canc Netw; 2022 Apr; 20(5):430-435. PubMed ID: 35378504
[TBL] [Abstract][Full Text] [Related]
13. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
14. [Pharmacological characteristics and clinical study results of Pemigatinib (Pemazyre
Kabu K; Takei S; Kondo M; Kitazawa K; Harada T
Nihon Yakurigaku Zasshi; 2021; 156(6):392-402. PubMed ID: 34719574
[TBL] [Abstract][Full Text] [Related]
15. Pemigatinib: First Approval.
Hoy SM
Drugs; 2020 Jun; 80(9):923-929. PubMed ID: 32472305
[TBL] [Abstract][Full Text] [Related]
16. Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.
Rizzo A
Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34066684
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.
Javle M; Lowery M; Shroff RT; Weiss KH; Springfeld C; Borad MJ; Ramanathan RK; Goyal L; Sadeghi S; Macarulla T; El-Khoueiry A; Kelley RK; Borbath I; Choo SP; Oh DY; Philip PA; Chen LT; Reungwetwattana T; Van Cutsem E; Yeh KH; Ciombor K; Finn RS; Patel A; Sen S; Porter D; Isaacs R; Zhu AX; Abou-Alfa GK; Bekaii-Saab T
J Clin Oncol; 2018 Jan; 36(3):276-282. PubMed ID: 29182496
[TBL] [Abstract][Full Text] [Related]
18. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma.
Merz V; Zecchetto C; Melisi D
Future Oncol; 2021 Feb; 17(4):389-402. PubMed ID: 33034201
[TBL] [Abstract][Full Text] [Related]
19. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.
Braun S; McSheehy P; Litherland K; McKernan P; Forster-Gross N; Bachmann F; El-Shemerly M; Dimova-Dobreva M; Polyakova I; Häckl M; Zhou P; Lane H; Kellenberger L; Engelhardt M
Expert Opin Investig Drugs; 2021 Nov; 30(11):1071-1080. PubMed ID: 34698609
[TBL] [Abstract][Full Text] [Related]
20. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]